

**THE UNIVERSITY OF MICHIGAN
REGENTS COMMUNICATION**

ACTION REQUEST

Subject: Commercialization Agreements with the University of Michigan

Action Requested: Approval of Commercialization Agreements

Preamble:

Statutory conflicts of interest situations were identified by Innovation Partnerships while reviewing commercialization agreements that then triggered a review by the Medical School Conflict of Interest Board and/or the OVPR Conflict of Interest Committee. Plans for management of the possible risks associated with the conflicts of interest will be developed and approved by the Board and/or Committee and may require agreement by the parties involved.

These proposed commercialization agreements (“Agreements”) fall under the State of Michigan Conflict of Interest Statute because employees of the University of Michigan (“University”) have outside activities, relationships, or interests in the companies described in Attachment A. The law permits such Agreements provided they are disclosed to the Board of Regents (“Regents”) of the University and approved in advance by a 2/3 vote.

Background:

These companies were formed to commercialize University technologies and desire to option, license, or reassign the University’s rights associated with them. Innovation Partnerships selected these companies as University partners and negotiated the terms of the proposed agreements in accordance with University policy and its accepted licensing principles.

Agreement Terms Include:

The University will retain ownership of the optioned, licensed, or reassigned technologies and may continue to further develop and use them internally. No use of University services or facilities, nor any assignment of University employees, is obligated or contemplated under the Agreements. Standard disclaimers of warranties and indemnification apply, and the Agreements may be amended by consent of the parties, such as adding related technology. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate. Terms specific to each Agreement are described in Attachment A.

Net Effect:

Innovation Partnerships has negotiated and finalized the terms of the option, license, or reassignment agreements for patents, technology, or content related to University technologies for particular fields of use. The companies will obtain the right to evaluate, use, and/or commercialize the University technologies. The net effects specific to each Agreement are described in Attachment A.

Recommendations:

These matters have been reviewed and approved by the Medical School Conflict of Interest Board and/or the OVPR Conflict of Interest Committee. In light of this disclosure and our finding that the Agreements were negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the Agreements between the University and the companies outlined in Attachment A.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Arthur Lupia', with a stylized flourish at the end.

Arthur Lupia
Vice President for Research and Innovation

September 2025

Attachment A

Agreement #1

Option Agreement between the University and AUTHENTIQ CORP. Reviewed by the OVPR Conflict of Interest Committee

Innovation Partnerships Intellectual Property File Information

Number	Title	Inventors
2020-126	Non-Destructive Imaging of Integrated Circuits for Counterfeit Detection	Parag Deotare, Zidong Li, Kanak Datta
2025-223	Authentication of nanofabrication processes of semiconductor chips	Parag Deotare, Zhaohan Jiang, Vigneshwar Dhavamani

Background

AUTHENTIQ CORP. was formed to commercialize technology for authenticating semiconductor integrated chips to enhance cyber security and desires to option the University's rights associated with the technology listed above.

Net Effects

- Worldwide exclusive
- Patents
- All fields of use
- Evaluation only

Agreement Terms

AUTHENTIQ CORP. will:

- Reimburse patent costs
- Pay an upfront fee

University Employee; University Title; Relationship with AUTHENTIQ CORP.

- Parag Deotare; Associate Professor, Electrical Engineering and Computer Science – Electrical and Computer Engineering (EECS – ECE) Division; Partial Owner

Agreement #2**Option Agreement between the University and Bloodscan Biotech Inc.
Reviewed by the OVPR Conflict of Interest Committee****Innovation Partnerships Intellectual Property File Information**

Number	Title	Inventors
5558	Label-Free High Throughput Microfluidic Device for Size-Based Separation of Cells	Hyeun Joong Yoon, Lianette Rivera Baez, Eric Lin, Sunitha Nagrath, Max Wicha, Diane Simeone
2022-135	Fast and Cost-Effective Isolation of Circulating Exosomes using Porous PDMS-Based Microsystem (PorousExoChip)	Sunitha Nagrath, Toontae Kang

Background

Bloodscan Biotech Inc. was formed to commercialize microfluidic devices for the isolation of circulating tumor cells and desires to option the University's rights associated with the technology listed above.

Net Effects

- Worldwide exclusive
- Patents
- For clinical diagnostics
- Evaluation only

Agreement Terms

Bloodscan Biotech Inc. will:

- Reimburse patent costs

University Employee; University Title; Relationship with Bloodscan Biotech Inc.

- Sunitha Nagrath; Professor, Chemical Engineering; Partial Owner

Agreement #3
**License Agreement between the University and Bloodscan Biotech Inc.
Reviewed by the OVPR Conflict of Interest Committee**
Innovation Partnerships Intellectual Property File Information

Number	Title	Inventors
5558	Label-Free High Throughput Microfluidic Device for Size-Based Separation of Cells	Hyeun Joong Yoon, Lianette Rivera Baez, Eric Lin, Sunitha Nagrath, Max Wicha, Diane Simeone
2022-135	Fast and Cost-Effective Isolation of Circulating Exosomes using Porous PDMS-Based Microsystem (PorousExoChip)	Sunitha Nagrath, Toontae Kang

Background

Bloodscan Biotech Inc. was formed to commercialize microfluidic devices for the isolation of circulating tumor cells and desires to license the University's rights associated with the technology listed above.

Net Effects

- Worldwide exclusive
- Patents
- Reagents for research use (excluding clinical diagnostics)
- Right to commercialize

Agreement Terms

Bloodscan Biotech Inc. will:

- Obtain the right to grant sublicenses
- Pay a royalty on sales
- Reimburse patent costs

The University will:

- Receive equity in Bloodscan Biotech Inc.
- Retain the right to purchase more equity in Bloodscan Biotech Inc.

University Employee; University Title; Relationship with Bloodscan Biotech Inc.

- Sunitha Nagrath; Professor, Chemical Engineering; Partial Owner

Agreement #4**Option Agreement between the University and Duvera Bio, Inc.
Reviewed by the Medical School Conflict of Interest Board****Innovation Partnerships Intellectual Property File Information**

Number	Title	Inventors
7453	Design and Synthesis of Novel Retinoids	Kent Johnson, James Varani, Andrew White, Hollis Showalter

Background

Duvera Bio, Inc. was formed to develop and commercialize therapeutic technology to treat acne and other skin conditions and desires to option the University's rights associated with the technology listed above.

Net Effects

- Worldwide exclusive
- Patents
- All fields of use
- Evaluation only

Agreement Terms

Duvera Bio, Inc. will:

- Reimburse patent costs

University Employee; University Title; Relationship with Duvera Bio, Inc.

- James Varani; Professor Emeritus, Pathology; Partial Owner
- Kent Johnson; Professor Emeritus, Pathology; Partial Owner

Agreement #5**License Agreement between the University and EMW Inc.
Reviewed by the OVPR Conflict of Interest Committee****Innovation Partnerships Intellectual Property File Information**

Number	Title	Inventors
2019-303	Entertain Me Well	Addie Weaver, Joe Himle, Anao Zhang
2025-526	Entertain Me Well: Washtenaw My Brother's Keeper (WMBK)	Addie Weaver, Joe Himle, Anao Zhang, Hedieh Briggs, James Greggs, Antonio Byrd, Devin Wilson, Sedeck Cheeks, Jahmari Thomas
2025-360	Entertain Me Well: Moms & Babies Feeling Better Together/Moms and Kids Feeling Better Together	Addie Weaver, Joe Himle, Anao Zhang, Maria Muzik
2025-361	Entertain Me Well: Mental Health Can't Wait	Addie Weaver, Joe Himle, Anao Zhang
2025-362	Entertain Me Well: Mind Your Total Health (MYTH)	Addie Weaver, Joe Himle, Anao Zhang
2025-363	Entertain Me Well: Doing Better on Dialysis	Addie Weaver, Joe Himle, Anao Zhang, Jonathan Segal

Background

EMW Inc. was formed to commercialize a cognitive behavioral therapy to advance depression and anxiety support for underserved populations and desires to license the University's rights associated with the technology listed above.

Net Effects

- Worldwide exclusive
- Copyrights
- All fields of use
- Right to commercialize

Agreement Terms

EMW Inc. will:

- Obtain the right to grant sublicenses

The University will:

- Receive equity in EMW Inc.

University Employee; University Title; Relationship with EMW Inc.

- Joseph Himle; Professor, Social Work; Partial Owner
- Addie Weaver; Associate Professor, Social Work; Partial Owner
- Anao Zhang; Associate Professor, Social Work; Partial Owner

Agreement #6
License Agreement between the University and General Orbit Company
Reviewed by the OVPR Conflict of Interest Committee
Innovation Partnerships Intellectual Property File Information

Number	Title	Inventors
2023-285	Three-sensor magnetometer for magnetically noisy environments	Lauro V. Ojeda, Mark Moldwin, Alex Paul Hoffmann, Eftyhia Zesta
2023-305	Quad-Mag for small satellites	Lauro V. Ojeda, Mark Moldwin, Alex Paul Hoffmann, Brady Parker Strabel, Matt Pellioni, Bret Bronner, Jacob Thoma, Leonardo Hector Regoli
2023-330	Michigan Space Magnetometer	Lauro V. Ojeda, Mark Moldwin, Jon Van Noord, Bret Bronner, Leonardo Hector Regoli, Curt Cooper
2024-319	Hybrid AC/DC Magnetometer with Attitude Determination and Control System	Lauro V. Ojeda, Mark Moldwin, James W. Cutler
2025-240	Self-Calibrating Magnetometer	Lauro V. Ojeda, Mark Moldwin, Julio Vata, Cole Jacob Dorman

Background

General Orbit Company was formed to commercialize new hybrid magnetometer and attitude determination and control system (HyMag-ADCS) technology and desires to license the University's rights associated with the technology listed above.

Net Effects

- Worldwide exclusive
- Patents
- All fields of use
- Right to commercialize

Agreement Terms

General Orbit Company will:

- Obtain the right to grant sublicenses
- Pay a royalty on sales
- Reimburse patent costs

The University will:

- Receive equity in General Orbit Company
- Retain the right to purchase more equity in General Orbit Company

University Employee; University Title; Relationship with General Orbit Company

- Mark Moldwin; Professor, Climate and Space Sciences and Engineering; Partial Owner
- Lauro Ojeda; Research Scientist, Mechanical Engineering; Partial Owner

Agreement #7**License Agreement between the University and Medication Data Science, Inc.
Reviewed by the OVPR Conflict of Interest Committee****Innovation Partnerships Intellectual Property File Information**

Number	Title	Inventors
2024-442	System Approach to Verifying Electronic Prescriptions (SAV ERx)	Corey Lester, Megan Whitaker
2026-030	SIG-Rx: an electronic prescription direction editor	Corey Lester, Megan Whitaker, Prem Ganesan

Background

Medication Data Science, Inc. was formed to develop and commercialize technology solutions that enhance safety, quality, and efficiency within the pharmacy and healthcare ecosystem and desires to license the University's rights associated with the technology listed above.

Net Effects

- Worldwide exclusive
- Copyrights and trademarks
- All fields of use
- Right to commercialize

Agreement Terms

Medication Data Science, Inc. will:

- Obtain the right to grant sublicenses

The University will:

- Receive equity in Medication Data Science, Inc.

University Employee; University Title; Relationship with Medication Data Science, Inc.

- Corey Lester; Assistant Professor, Clinical Pharmacy; Partial Owner

Agreement #8
**License Agreement between the University and MELD Health, Inc.
Reviewed by the OVPR Conflict of Interest Committee**
Innovation Partnerships Intellectual Property File Information

Number	Title	Inventors
5575	Pain Tracking and Analysis Tool for Mobile Platforms	Alexandre DaSilva, Eric Maslowski, Sean Petty, Sean Sheehan
2025-101	BODY-AI	Alexandre DaSilva, Xiaosu Hu, Fabio Thiers

Background

MELD Health, Inc. was formed to commercialize an advanced pain tracking and patient physician collaboration platform and desires to license the University's rights associated with the technology listed above.

Net Effects

- Worldwide exclusive
- Patents and copyrights
- All fields of use
- Right to commercialize

Agreement Terms

MELD Health, Inc. will:

- Obtain the right to grant sublicenses
- Pay a royalty on sales
- Reimburse patent costs
- Pay an upfront fee

The University will:

- Receive equity in MELD Health, Inc.
- Retain the right to purchase more equity in MELD Health, Inc.

University Employee; University Title; Relationship with MELD Health, Inc.

- Alexandre DaSilva; Professor, Biologic and Materials Science; Partial Owner
- Jim Arthurs; New Product Planning Manager, Innovation Partnerships; Board of Directors Member
- David Gramlich; Programmer II (temp), Prosthodontics; Partial Owner

Agreement #9**Option Agreement between the University and Y-Reproductive Technologies, Inc.
Reviewed by the Medical School Conflict of Interest Board****Innovation Partnerships Intellectual Property File Information**

Number	Title	Inventors
2024-053	Generation of tests like somatic cell organoids	Saher Sue Hammoud, Umesh Kumar
2021-502	Generation of human sertoli cells to support in vivo and in vitro gametogenesis	Saher Sue Hammoud, Umesh Kumar, Veda Yadegiri, Jun Li
2025-659	Development of complex miniature testis	Saher Sue Hammoud, Umesh Kumar, Lindsay Moritz

Background

Y-Reproductive Technologies, Inc. was formed to commercialize innovations that describes the development of artificial testes for the purpose of studying and treating male infertility and desires to option the University's rights associated with the technology listed above.

Net Effects

- Worldwide exclusive
- Patents
- For research reagents and human therapeutics
- Evaluation only

Agreement Terms

Y-Reproductive Technologies, Inc. will:

- Pay an upfront fee

University Employee; University Title; Relationship with Y-Reproductive Technologies, Inc.

- Saher Sue Hammoud; Associate Professor, Human Genetics; Partial Owner